4-(2,4-dimethylbenzyl)morpholine | 76252-49-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2,4-dimethylbenzyl)morpholine
• 英文别名: 4-[(2,4-dimethylphenyl)methyl]morpholine
• CAS: 76252-49-8
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: FMDYPXVOQVNISN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(氯甲基)-2,4-二甲苯 、 吗啉 生成 4-(2,4-dimethylbenzyl)morpholine
  参考文献：
  名称：

  GASANOVA M. M.; ARABOV A. K.; VABAXANOV R. A.; AXUNDOV A. A., MEHPYZHEHLEHR. AZSSR ELMLEHR AKAD., DOKL. AN AZSSR, 1979, 35, HO 11, 67-7+

  摘要：

  DOI：

文献信息

• Cyclization of dialkylpropyn-1-yl(allyl)(3-isopropenylpropyn-2-yl)ammonium bromides and water-base cleavage of 2,2-dialkyl-5-methyl-2,6,7,7<i>a</i>-tetrahydro-1<i>h</i>-isoindolium and 2,2-dialkyl-5-methylisoindolinium bromides
  作者：Emma H. Chukhajian、Martiros K. Nalbandyan、Hasmik R. Gevorkyan、Eliza H. Chukhajian、Henrik A. Panosyan、Armen G. Ayvazyan、Rafael A. Tamazyan

  DOI：10.1002/jhet.5570450309

  日期：2008.5

  yn-2-yl)ammonium bromides under base-catalyzed condition instantly undergo intramolecular cyclization. The cyclization of dialkylpropyn-1-yl(3-isopropenylpropyn-2-yl)ammonium bromides leads to the formation of 2,2-dialkyl-5-methylisoindolinium salts. In case of allyl analogs, instead of the expected 2,2-dialkyl-6-methyl-3a,4-dihydroisoindolinium salts their isomeric forms - 2,2-dialkyl-5-methyl-2,6

  在碱催化条件下，二烷基丙炔-1-基（或烯丙基）（3-异丙烯基丙炔-2-基）溴化铵立即经历分子内环化。二烷基丙炔-1-基（3-异丙烯基丙炔-2-基）溴化铵的环化导致形成2，2-二烷基-5-甲基异吲哚鎓盐。在烯丙基类似物，而不是预期的2,2-二烷基-6-甲基- 3的情况下一个，4- dihydroisoindolinium盐及其异构体形式- 2,2-二烷基-5-甲基2,6,7,7一-获得四氢-1 H-异吲哚溴化物。在碱性介质中，它们被转化为二氢异吲哚鎓盐，其在两个方向（1,2,1,6）上的裂解导致异构的二烷基-1,4-二甲基-和2,4-二甲基苄基胺的混合物。
• [EN] SMALL MOLECULE MODULATORS OF IL-17<br/>[FR] MODULATEURS D'IL-17 À PETITES MOLÉCULES
  申请人：LEO PHARMA AS

  公开号：WO2020182666A1

  公开（公告）日：2020-09-17

  The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及按照式I的化合物及其药学上可接受的盐、水合物或溶剂化合物。该发明进一步涉及将这些化合物用于治疗、包含这些化合物的药物组合物、使用这些化合物治疗疾病（例如皮肤疾病）的方法，以及将这些化合物用于制造药物。
• Vinyl compounds as FGFR and VEGFR inhibitors
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US10519133B2

  公开（公告）日：2019-12-31

  FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

  提供了表皮生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）抑制剂，并特别公开了作为表皮生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）抑制剂的式(1)或式(II)所代表的化合物、其药学上可接受的盐或同系物。
• VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20180222886A1

  公开（公告）日：2018-08-09

  FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.
• SMALL MOLECULE MODULATORS OF IL-17
  申请人：LEO PHARMA A/S

  公开号：US20220162191A1

  公开（公告）日：2022-05-26

  The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.